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Abstract
Background: Postoperative epidural fibrosis may contribute to between 5% to 60% of the poor
surgical outcomes following decompressive surgery. Correlations have been reported between
epidural scarring and radicular pain, poor surgical outcomes, and a lack of any form of surgical
treatment. The use of spinal endoscopic adhesiolysis in recent years in the management of chronic
refractory low back and lower extremity pain has been described.
Methods:  A prospective, randomized, double-blind trial was conducted to determine the
outcome of spinal endoscopic adhesiolysis to reduce pain and improve function and psychological
status in patients with chronic refractory low back and lower extremity pain. A total of 83 patients
were evaluated, with 33 patients in Group I and 50 patients in Group II. Group I served as the
control, with endoscopy into the sacral level without adhesiolysis, followed by injection of local
anesthetic and steroid. Group II received spinal endoscopic adhesiolysis, followed by injection of
local anesthetic and steroid.
Results: Among the 50 patients in the treatment group receiving spinal endoscopic adhesiolysis,
significant improvement without adverse effects was shown in 80% at 3 months, 56% at 6 months,
and 48% at 12 months. The control group showed improvement in 33% of the patients at one
month and none thereafter. Based on the definition that less than 6 months of relief is considered
short-term and longer than 6 months of relief is considered long-term, a significant number of
patients obtained long-term relief with improvement in pain, functional status, and psychological
status.
Conclusion: Spinal endoscopic adhesiolysis with targeted delivery of local anesthetic and steroid
is an effective treatment in a significant number of patients with chronic low back and lower
extremity pain without major adverse effects.
Published: 06 July 2005
BMC Anesthesiology 2005, 5:10 doi:10.1186/1471-2253-5-10
Received: 08 November 2004
Accepted: 06 July 2005
This article is available from: http://www.biomedcentral.com/1471-2253/5/10
© 2005 Manchikanti et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Anesthesiology 2005, 5:10 http://www.biomedcentral.com/1471-2253/5/10
Page 2 of 14
(page number not for citation purposes)
Background
Postoperative epidural fibrosis, the formation of dense
scar tissue adjacent to the dura mater following surgical
laminectomy, may play a role in up to 60% of the poor
surgical outcomes following decompressive surgery [1-3].
A correlation between peridural scarring and radicular
pain [4-7], and poor clinical outcomes [8,9] has been
reported by some, while others [10-13] have questioned
the role of epidural fibrosis as a causative factor. Increased
complication rates have been reported with revision spine
surgery with increased occurrence of dural tears, nerve
root injury, and bleeding [14,15]. Phillips and Cunning-
ham [16] reported that no form of surgical treatment or
adhesion lysis procedure was safe or effective for post-
lumbar laminectomy syndrome.
Epidural fibrosis results from the invasion of postopera-
tive hematoma by dense fibrous tissue originating from
the periosteum and within the deep surface of the paraver-
tebral musculature [17,18]. Epidural fibrosis may extend
into the neural canal and adhere to the dura mater and
nerve roots, with mechanical tethering of nerve roots or
dura by adhesions, which may in turn contribute to per-
sistent back and leg pain following lumbar laminectomy.
However, epidural fibrosis also may develop without sur-
gical intervention, secondary to annular tear, hematoma,
infection, or intrathecal contrast media [18-20].
Perineural fibrosis can render nerve roots hyperesthetic
and hypersensitive to compression forces by interfering
with cerebrospinal fluid-mediated nutrition [6] or by
making the nerve susceptible to injury [7].
A moderate proportion of patients show improvement in
pain and functional level with interventional pain man-
agement procedures, including fluoroscopically-directed
epidural steroid injections and percutaneous adhesiolysis
utilizing a special catheter [21,22]. In addition, initial
clinical studies of spinal endoscopic adhesiolysis [23-29]
and a preliminary report of a randomized controlled trial
[30] showed improved clinical outcomes. However, a
recent prospective, randomized, double-blind trial [31]
comparing caudal epidural with targeted steroid place-
ment on affected nerve roots during spinal endoscopy for
chronic sciatica, concluded that targeted placement of
steroid did not significantly reduce pain intensity and anx-
iety and depression compared with caudal epidural ster-
oid injection.
Most studies utilized post lumbar laminectomy syndrome
or epidural fibrosis as inclusion criteria, whereas one
study [28] included patients with lumbar spinal stenosis,
and another [31] exclusively studied patients without his-
tory of surgery. In addition, some studies [26,27,30] spe-
cifically described inclusion criteria as patients without
long-term improvement following fluoroscopically
directed epidural steroid injections and one-day percuta-
neous adhesiolysis. Consequently, these studies represent
heterogenous populations. Even though retrospective
evaluations [26,27] have shown the effectiveness of spinal
endoscopic adhesiolysis in patients after lack of long-term
effect following fluoroscopically-directed caudal epidural
steroid injections and one-day percutaneous adhesiolysis,
the effectiveness has not been demonstrated in controlled
trials.
Spinal endoscopy also has been utilized for diagnostic
purposes. Even though multiple authors have described
various types of findings, including the identification of
inflammation with an endoscope, neither the reliability
nor the clinical utility of spinal endoscope as a diagnostic
tool has been established [23-25,28,29]. Consequently,
no attempt was made to evaluate the diagnostic utility of
spinal endoscopy.
This randomized, double-blind, controlled trial of spinal
endoscopic adhesiolysis and targeted delivery of steroids
was designed to evaluate their effectiveness in patients
with chronic low back and lower extremity pain who
lacked significant response to fluoroscopically-directed
epidural steroid injections and one-day percutaneous
adhesiolysis with hypertonic saline neurolysis, as well as
to other conservative modalities of treatment.
Methods
This study was designed to evaluate the effectiveness of
spinal endoscopic adhesiolysis in chronic, refractory low
back and lower extremity pain. The study was undertaken
in an interventional pain management practice (a spe-
cialty referral center) in a private practice setting, in
accordance with the guidelines for randomized controlled
trials [32,33], and the quality checklists of systematic
reviews [32,34-39]. The trial also was designed to meet cri-
teria of a pragmatic or a practical clinical trial [30,40,41].
The protocol was approved by the Institutional Review
Board of the Ambulatory Surgery Center where the study
was conducted. The objective was to evaluate the effective-
ness of spinal endoscopic adhesiolysis compared to cau-
dal epidural steroid injection. The design consisted of a
control group and an intervention group. Group I (con-
trol group) was treated with introduction of the spinal
endoscope up to the S3 level, followed by injection of a
local anesthetic and steroid. Group II (intervention
group) was treated with appropriate spinal endoscopic
adhesiolysis at L4, L5 or S1 level(s) unilaterally or bilater-
ally based on symptomatology, followed by a targeted
injection of local anesthetic and steroid.
Inclusion and exclusion criteria
The majority of participants in this study were identified
from existing patients of the interventional painBMC Anesthesiology 2005, 5:10 http://www.biomedcentral.com/1471-2253/5/10
Page 3 of 14
(page number not for citation purposes)
management practice. Eligible new patients were screened
and identified as candidates for the program.
Inclusion criteria
patients between 18 and 65 years of age with a history of
chronic low back and lower extremity pain of at least two
year's duration, without facet joint pain based on control-
led comparative local anesthetic blocks, and without sig-
nificant improvement with conservative treatment
including fluoroscopically-directed epidural injections
and one-day percutaneous adhesiolysis with hypertonic
saline neurolysis, and willingness to participate in the
clinical trial were enrolled.
Criteria for lack of significant response to caudal epidural
steroid injections was pain relief (≥ 50%) for one week or
less following a second epidural steroid injection, and
relief of four weeks or less following a third epidural ster-
oid injection or any of subsequent epidural steroid injec-
tions. Criteria for lack of response to one-day
percutaneous adhesiolysis with hypertonic saline neurol-
ysis was considered as lack of response to the first adhesi-
olysis procedure, less than two months of pain relief (≥
50%) following the second or subsequent procedures.
Exclusion criteria
patients with cauda equina syndrome, compressive radic-
ulopathy, surgical intervention in the previous six
months, opioid abuse and dependency evaluated by
adherence monitoring, including random drug testing
and opioid use of no greater than hydrocodone 100 mg
per day, methadone 60 mg or morphine 100 mg or equiv-
alent doses of other drugs; uncontrolled major depression
or psychiatric disorders; uncontrolled or acute medical ill-
nesses including severe cardiac, pulmonary, or other dis-
orders; chronic conditions that could interfere with the
interpretations of the outcome assessments such as severe
hip or knee arthritis, neuropathy, or other disorders; preg-
nant or lactating women; history of adverse reaction to
local anesthetic or steroids; inability to understand the
informed consent and protocol; or inability to be posi-
tioned in the prone position during the procedure [30].
Evaluation
All patients were provided with the protocol and the
informed consent document approved by the Institu-
tional Review Board for this study. The informed consent
document described the details of the trial.
The screening evaluation consisted of demographic data,
medical/surgical history with co-existing diseases, radio-
graphic investigations, physical examination, psychologi-
cal evaluation with Pain Patient Profile (P-3®), Visual
Analogue Scale (VAS) pain scores, work status, Oswestry
Disability Index 2.0, and lumbar spine range of motion
with ARCON ROM computerized dual inclinometer sys-
tem, based on AMA "Guides to the Evaluation of Perma-
nent Impairment" validity criterion utilizing three
consecutive measurements with ± 5° or ± 10% of mean
value.
Interventions
All patients in both groups were provided identical prep-
aration. All procedures were performed using fluoroscopy
in an ambulatory surgery center in sterile operating rooms
by one physician (LM).
Procedure
The procedure included appropriate preparation with
intravenous access, pre-procedure antibiotic administra-
tion, sterile preparation, and appropriate sedation with
fentanyl and midazolam. Access to the epidural space was
obtained with a RK®  needle. An epidurogram was
obtained which identified filling defects and/or epidural
fibrosis. Adhesiolysis was carried out in the intervention
group utilizing the myeloscope® spinal endoscopic video-
guided catheter system and introducer system, with final
positioning of the fiberoptic endoscope on the side and
level of the defect and the source of pain with an addi-
tional injection of contrast to identify adhesiolysis, fol-
lowed by targeted injection of local anesthetic and steroid.
Following initial epidurography in the control group, a
0.9 mm guidewire was inserted through the needle, which
was advanced under fluoroscopic guidance to S3 level.
Then, a 2-mm × 17.8-cm dilator with catheter (sheath)
was passed over the guidewire again up to S3. At that time,
a 0.8-mm fiberoptic spinal endoscopic video-guided sys-
tem was introduced into the catheter through the valve
and was advanced until the tip was positioned at the distal
end of the catheter through the valve, as determined by
video and fluoroscopic images not to exceed S3. Follow-
ing this, 10 mL of 1% lidocaine and 6 mg to 12 mg of bet-
amethasone or 40 mg to 80 mg of methylprednisolone
were injected through the epiduroscope. Following the
completion of the procedure, the endoscope was removed
and appropriate sterile Bioclusive dressing was applied.
In the intervention group, following initial epidurogra-
phy, a 0.9-mm guidewire was inserted through the needle
(occasionally facilitated by a small incision with a #11
straight blade), which was advanced under fluoroscopic
guidance to the level of suspected pathology. Following
this, a 2-mm × 17.8-cm dilator with catheter (sheath) was
passed over the guidewire. Once the catheter was
advanced to the tip of the guidewire, the wire was
removed. A 0.8-mm fiberoptic spinal endoscopic video-
guided system was introduced into the catheter through
the valve and advanced until the tip was positioned at the
distal end of the catheter, as determined by video andBMC Anesthesiology 2005, 5:10 http://www.biomedcentral.com/1471-2253/5/10
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fluoroscopic images. In conjunction with gentle irrigation
using normal saline, the catheter and fiberoptic myelo-
scope were manipulated and rotated in multiple direc-
tions, with visualization of the nerve roots at various
levels. Painful nerve root was confirmed by endoscopic
manipulation, based on pre-procedural clinical and radi-
ographic evaluation. Adhesiolysis and decompression
were carried out by distension of the epidural space with
normal saline and by mechanical means utilizing the
fiberoptic endoscope. Adhesiolysis was confirmed by
injection of non-ionic contrast material (Omnipaque
240®) and an epidurogram was performed on at least two
occasions. The volume of sodium chloride solution uti-
lized for irrigation was closely monitored. The protocol
limited the total volume of contrast and sodium chloride
solution not to exceed 100 mL. Adhesiolysis was limited
to L4, L5 or S1 levels, either unilaterally or bilaterally. Fol-
lowing completion of the procedure, 4 mL to 8 mL of lido-
caine 1%, preservative free, mixed with either 6 mg or 12
mg of betamethasone or 40 mg or 80 mg of methylpred-
nisolone was injected after assuring that there was no evi-
dence of subarachnoid leakage of contrast. The injection
of betamethasone or methylprednisolone was based on
its availability in the market. Methylprednisolone was uti-
lized if betamethasone was not available. If pathology was
identified at multiple levels, the procedure was carried out
at those levels, and the injectate was given in divided
doses. If there was a question of subarachnoid leakage of
the contrast, a Racz catheter® was passed into the epidural
space, and a mixture of local anesthetic was injected very
slowly in incremental doses, followed by injection of the
steroid if satisfactory follow-up was obtained without any
subarachnoid blockade. Following the injection of local
anesthetic and steroid, the scope was removed and appro-
priate sterile Bioclusive dressing was applied.
Co-interventions
No specific co-interventions were offered. Baseline drug
therapy was allowed to be continued with no changes
being made towards increasing opioids until after the
unblinding and/or documented failure of intervention.
However, opioid decreases were implemented based on
improvement in functional status and reduction in pain
following the interventions. Self-directed exercises as tol-
erated were also prescribed.
Outcomes assessment
Outcomes were assessed at 3-month, 6-month, and 12-
month intervals post-treatment with the Visual Analogue
Scale (VAS) pain scale, Oswestry Disability Index 2.0,
work status, opioid intake, range of motion measurement
by ARCON ROM computerized evaluation, and psycho-
logical evaluation by P-3. They were compared to baseline
within both groups and with each other at various time
intervals. Duration of relief was judged to be short-term,
if relief was less than 6 months. If relief lasted for at least
6 months, it was considered long-term. Significant relief
was defined as pain relief of 50% or greater.
VAS was measured on a 10 cm scale. P-3 psychological
evaluation [42] and Oswestry Disability Index 2.0 [43]
were assessed by administration of appropriate question-
naires. Range of motion was evaluated by a certified phys-
ical therapist, blinded to the type of treatment. Based on
P-3, scores of 55 or higher were considered positive for a
diagnosis of depression, whereas, scores of 56 or higher
were considered to provide the diagnosis of anxiety or
somatization.
Opioid intake was determined as none, mild, moderate,
or heavy based on the dosage, frequency and schedule of
the drug as follows: Considered as mild was an intake of
Schedule IV opioids, i.e., propoxyphene napsylate, penta-
zocine hydrochloride, tramadol hydrochloride up to a
maximum of four times, or hydrocodone less than 40 mg
per day; considered moderate was an intake of Schedule
III opioids, i.e., hydrocodone, up to 40 mg per day; and
considered heavy was an intake of Schedule II opioids,
i.e., oxycodone, morphine, meperidine, transdermal fen-
tanyl, and methadone, in any dosage.
Employment and work status (employed, unemployed,
housewife, disabled, and retired) were determined from
the pre-treatment and post-treatment work status. Only
employed and unemployed patients were considered to
be eligible for employment, whereas disabled patients
and retired patients were considered not employable.
Patients in the "housewife" category were considered nei-
ther employable nor unemployable.
Statistical methods
Study design
Randomization was 2:3 with two patients randomized to
the control group (Group I), for every three patients rand-
omized to the spinal endoscopic adhesiolysis group
(Group II). Randomization was performed by the statisti-
cian using a computer-generated random allocation
sequence in blocks of 15 patients.
The random allocation was concealed from the physician
doing the procedure and personnel in the operating room
until the intervention. Randomization was not revealed to
the personnel in the recovery room or to the reviewing
physician. After treatment, the patient was never in con-
tact with anyone with knowledge to the randomization
assignment, until after the unblinding was performed.
Unblinding was considered at a patient's request and/or
treatment was considered a failure at 3 months or later. All
other patients were unblinded at 12 months. PatientsBMC Anesthesiology 2005, 5:10 http://www.biomedcentral.com/1471-2253/5/10
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were also given an option to discontinue or to withdraw
from the study for any and all reasons. They were consid-
ered withdrawn if follow-up was lost.
Intent-to-treat analysis
An intent-to-treat analysis was performed by including all
subjects by carrying forward the last observation.
Statistical analysis
Demographic data were analyzed by means of the Stu-
dent's t test and the chi-squared test. Fischer's exact test
was used wherever the expected value was less than five.
For analyzing Outcome measurement based on Visual
Analogue Scale (VAS) Report and Oswestry Disability
Index, range of motion (ROM), depression, anxiety and
somatization scores, student's t test (parametric) and The
Mann-Whitney U test (non-parametric) were used to test
mean differences between groups. A paired t test and Wil-
coxon signed-rank test were used to compare pre-and
post-treatment results for individual patients. When
results from both parametric and non-parametric tests
were similar, P  values from the parametric tests were
reported in the tables and text. Results were considered
statistically significant if the P value was less than 0.05.
Results
The study was conducted from January 2002 through
December 2003. As per the protocol, initial results were
published in 2003; this preliminary report included a 6
month follow up with 16 patients in caudal epidural ster-
oid injection group, and 23 patients in spinal endoscopy
group [30]. To facilitate this publication, results of two
patients in the control group and 12 patients in the inter-
vention group were unblinded by the statistician for pur-
poses of the evaluation and preliminary publication. This
unblinding was not revealed to investigators, other staff,
and the participants of the study. Consequently, 39
patients reported at 6 months were also included in the
present report.
A diagram illustrating flow of the trial is depicted as Figure
1. In the control group, one patient was lost to follow-up
after 3 months. In the intervention group, two patients
withdrew from the study. One patient experienced no
improvement, withdrew from the study, and underwent
further surgical intervention. The second patient in the
intervention group reported no significant relief and with-
drew from the study and refused further follow-up. Intent
to treat analysis was performed by using baseline or last
follow-up data in both groups. All patients received only
one treatment during the study period. Patients were con-
sidered withdrawn if they received any other interven-
tional techniques. Last follow-up was utilized for analysis
with 3-month data at 6 months and 12 months in 15
patients, and 6-month data at 12 months in two patients
in the control group. In the intervention group, baseline
data was utilized in two patients. In the intervention
group, of the 11 patients unblinded at 3 months, five of
them participated in outcomes assessment at 6 months
and 12 months while six of them participated only at 6
months assessment. Thus, 3 month assessment results
were utilized at 6 months and 12 months, whereas the
results of 6 month assessments were utilized at 12 months
in eight patients (six patients from 3 month unblinding
and two patients from 6 month unblinding).
Demographic characteristics
Table 1 illustrates the demographic characteristics. All the
patients presented with back and lower extremity pain.
Most patients had pain with unilateral symptoms, while
bilateral symptoms were seen in 12% of the patients in
each group.
Procedural characteristics
In the control group, of the four patients (12%) with bilat-
eral back and lower extremity pain, two patients received
12 mg of betamethasone and two patients received 80 mg
of methylprednisolone. Of the remaining 29 patients, 16
patients received 6 mg of betamethasone and 13 patients
received 40 mg of methylprednisolone. The volume of
contrast was 8.6 ± 1.25 mL with a range of 8 to 12 mL
(Table 2).
In the intervention group, adhesiolysis was performed
bilaterally in six patients (12%). Adhesiolysis was per-
formed at one level in two patients, at two levels in 47
patients, and at four levels in one patient. Unilateral adhe-
siolysis was performed in only one patient at L4 level. No
bilateral adhesiolysis was performed at L4. Most com-
monly, adhesiolysis was performed at L5 and S1. The vol-
ume of sodium chloride solution injected was 55.0 ±
11.07 mL with a range of 35 to 70 mL. The volume of con-
trast was 11.2 ± 2.74 mL with volumes ranging from 8 to
16 mL. There were no cases of subarachnoid blockade
identified prior to injection of local anesthetic and ster-
oid. Thus, although it was available as part of the proto-
col, a Racz catheter was not used for any patient procedure
in the study. Twelve milligrams of betamethasone in 8 mL
of 1% lidocaine was injected in two patients and 80 mg of
methylprednisolone in 8 mL of 1% lidocaine was injected
in four patients, 6 mg of betamethasone in 4 mL of 1%
lidocaine was injected in 28 patients, and 40 mg of meth-
ylprednisolone in 4 mL of 1% lidocaine was injected in 16
patients (Table 2).
Outcome measures
A significant proportion of patients in the spinal endo-
scopic adhesiolysis group showed pain relief compared to
the control group, as well as compared to the baseline
findings (Fig 2).BMC Anesthesiology 2005, 5:10 http://www.biomedcentral.com/1471-2253/5/10
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Significant pain relief (≥ 50%) in months was calculated
for both groups. Calculations for all patients showed that
significant relief was seen for 0.7 ± 0.73 months in the
control group, whereas, 7.6 ± 4.7 months of relief was
noted for the intervention group. Significant pain relief
was longer in the intervention group. Duration of signifi-
cant relief (≥ 50%) (mean ± SD) was 9.3 ± 3.6 months in
patients considered as successful (40 of 50).
Schematic depiction of patient flow during the trial Figure 1
Schematic depiction of patient flow during the trial.
                     Randomization  
               2:3 
        83  patients
Patients deemed eligible and evaluated 
162
Patients Excluded 
 Inclusion Criteria were not met = 20 
 Refused to Participate = 59 
Group I – Control 
x No endoscopic adhesiolysis  
x Steroid injection 
   33 patients received control treatment 
Group II  
x Endoscopic adhesiolysis  
x Steroid injection 
   50 patients received intervention 
x Patients lost to follow-up = 1 
x Patients discontinuing intervention = 0 
x Patients unblinded at 3 months = 14 
x Patients unblinded at 6 months = 2 
x Patients unblinded at 12 months = 16 
x Patients withdrawn from study = 2 
x Patients discontinuing intervention = 0 
x Patients unblinded at 3 months = 11 
x Patients unblinded at 6 months = 2 
x Patients unblinded at 12 months = 35 
x Patients included in analysis = 33 
x Patients excluded from analysis = 0 
x Intent to treat analysis was performed by using 
   3-month data at 6 months and 12 months in 15 
   patients 
x Intent to treat analysis was performed in 2 
   patients using 6-month data at 12 months  
x Patients included in analysis = 50 
x Patients excluded from analysis = 0 
x Intent to treat analysis was performed  
 by using baseline data for 2 patients at 3, 6, 
and 12 months 
x Three month data was utilized at 6 months 
and 12 months in 6 patients 
x Six-month data was used at 12 months in 8 
patients  BMC Anesthesiology 2005, 5:10 http://www.biomedcentral.com/1471-2253/5/10
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In the control group, the proportion of patients with sig-
nificant relief greater than 50% at 1 month was 33%, and
at 3 months, 6 months, and 12 months was 0. By contrast,
in the intervention group relief was 90% at 1 month, 80%
at 3 months, 56% at 6 months, and 48% at 12 months
(Fig. 3).
Functional outcome measurement was carried out based
on Oswestry Disability Index 2.0. Significant improve-
ments were seen in the intervention group compared to
baseline in the same group, as well as compared to the
control group (Fig. 4).
Analysis of range of motion evaluations showed signifi-
cant improvements in the intervention group compared
to the baseline, as well as the control group at intervals of
3 months, 6 months, and 12 months (Table 3).
Table 4 illustrates psychological outcomes of depression,
anxiety, and somatization derived from P-3 scores.
Significant improvement was noted in psychological
parameters in the intervention group compared to the
control group, as well as to baseline status in the treat-
ment group.
Patients were evaluated for opioid intake, which was rated
from none to significant as described in the methods sec-
tion. Significant opioid intake was 40% in Group II at the
end of 12 months, compared to 74% at baseline. For
Group I, significant opioid usage was 55% at 12 months,
compared to 61% at baseline.
Evaluation of employment status showed that in the inter-
vention group employment increased to 32% at 12
months from 2% at baseline as compared to 6% at base-
Table 1: Demographic characteristics
Group I Group II
Number of patients 33 50
Age (Years) Mean ± SD 47 ± 9.4 50 ± 9.0
Gender Male 54% (18) 36% (18)
Female 46% (15) 64% (32)
Height (Inches) Mean ± SD 66 ± 3.6 66 ± 3.5
Weight (Lbs) Mean ± SD 181 ± 42.4 174 ± 36.8
Duration of pain (years) Mean ± SD 12.4 ± 5.9 11.8 ± 6.5
Mode of onset of the pain Traumatic 39% (13) 46% (23)
Non-traumatic 61% (20) 54% (27)
Back and lower extremity pain 100% (33) 100% (50)
Bilateral pain 12% (4) 12% (6)
History of previous surgery 73% (24) 84% (42)
Epidural fibrosis on MRI 73% (24) 84% (42)
Disc herniation on MRI 12% (4) 10% (5)
Table 2: Description of procedural characteristics
Group I 33 Group II 50
Betamethasone
12 mg 6% (2) 4% (2)
6 mg 48% (16) 56% (28)
Total 55% (18) 60% (30)
Methylprednisolone
80 mg 6% (2) 8% (4)
40 mg 39% (13) 32% (16)
Total 45% (15) 40% (20)
Contrast in mL Mean ± SD 8.6 ± 1.25 11.2 ± 2.74
Range 8 – 12 8 – 16
Sodium chloride solution for irrigation in mL Mean ± SD None 55.0 ± 11.07
Range 35 – 70
() indicates number of patientsBMC Anesthesiology 2005, 5:10 http://www.biomedcentral.com/1471-2253/5/10
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Outcome measurement based on Visual Analogue Scale report Figure 2
Outcome measurement based on Visual Analogue Scale report.
Proportion of patients with significant relief (≥ 50%) at 1 month, 3 months, 6 months and 12 months Figure 3
Proportion of patients with significant relief (≥ 50%) at 1 month, 3 months, 6 months and 12 months.
0
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*# *#
Baseline      3 months      6 months     12 months                       Baseline     3 months      6 months      12 months 
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# Indicates significant difference within the group compared to baseline (P = 0.001) 
* Indicates significant difference with Group I at the time of evaluation (P = 0.001) 
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line and at 12 months in the control group. As illustrated
in Table 5, almost all the patients deemed employable in
the intervention group were employed at 12 months, in
contrast to no change noted in the control group. In
addition, in the intervention group, eight patients disa-
bled at baseline were also employed at 12 months. There
were no patients in this study with active workers' com-
pensation injury cases or litigation.
Blinding
The blinding was judged to be satisfactory. Following the
treatment, and within one hour prior to discharge,
The Outcome Measurement Based on Oswestry Disability Index Figure 4
The Outcome Measurement Based on Oswestry Disability Index.
Table 3: Analysis of range of motion evaluation
Baseline 3 months 6 months 12 months
Group I Group II Group I Group II Group I Group II Group I Group II
33 50 33 50 33 50 33 50
Flexion (Normal 
60°)
Mean ± SD 25.4 ± 10.0 25.9 ± 11.4 26.6 ± 10.3 35.8*# ± 11.7 25.8 ± 10.4 36.7*# ± 13.7 25.6 ± 10.3 35.7*# ± 14.4
Extension 
(Normal 25°)
Mean ± SD 9.7 ± 3.9 9.0 ± 3.3 10.9 ± 5.1 14.7*# ± 5.3 10.5 ± 5.1 15.8*# ± 6.5 10.9 ± 5.3 16.3*# ± 7.0
Lateral Flexion 
(Normal 25°)
Mean ± SD 8.1 ± 2.9 8.4 ± 2.8 7.9 ± 3.0 14.0*# ± 5.3 7.8 ± 3.0 14.6*# ± 6.1 7.7 ± 2.8 15.1*# ± 6.8
* Indicates significant difference with Group I (P = 0.002)
# Indicates significant difference within the Group compared to baseline (P = 0.001)
0
10
20
30
40
#*
#*
#*
      34 + 5.6       33 + 6.2       33 + 5.8     33 + 6.4                            36 + 4.5       26 + 12.8     25 +11.7      25 + 12.7 
     Baseline      3 months     6 months     12 months                         Baseline       3 months    6 months     12 months
                       Group I                          Group II 
# Indicates significant difference within the group compared to baseline (P = 0.001) 
* Indicates significant difference with Group I at the time of evaluation (P = 0.001) BMC Anesthesiology 2005, 5:10 http://www.biomedcentral.com/1471-2253/5/10
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patients were asked what treatment they believed they had
received. Twenty-six of 33 patients in Group I and 42 of 50
patients in Group II believed they had received spinal
endoscopy. Two patients in Group I and two patients in
Group II were unable to theorize as to which procedure
they may have received. The remaining patients guessed
the wrong treatment. There was no significant difference
among the groups as to whether they believed they had
received the endoscopy or epidural steroid injection.
Adverse events
There was one case of subarachnoid block in Group II,
identified after completion of the procedure and injection
of local anesthetic and steroid. No adverse effects were
noted in this patient. There were no other adverse events
noted.
Discussion
This randomized, double-blind, controlled evaluation
demonstrated that following spinal endoscopic adhesiol-
ysis a significant proportion of patients with chronic,
refractory low back and lower extremity pain experienced
significant pain relief (≥ 50%) at 3 months (80%), 6
months (56%), and at 12 months (48%), compared to
the control group with only 33% of patients showing
improvement at 1 month, and none thereafter. Associated
improvements in VAS scores, Oswestry Disability Index,
range of motion, and psychological status were also noted
as compared to baseline measurements and results of the
control group. These results are important in that the
patients in this study represented a subset of patients who
have not only failed multiple conservative modalities of
management but also lacked significant, or long-term,
Table 4: Analysis of psychological status
Baseline 12 months
Group I Group II Group I Group II
33 50 33 50
Depression Diagnosis (≥ 55) 61% (20) 68% (34) 58% (19) 34%*(17)
Score Mean ± SD 56.9 ± 8.8 57.0 ± 9.9 55.5 ± 10.6 47.8*# ± 10.4
Anxiety Diagnosis (≥ 56) 58% (19) 62% (31) 55% (18) 28%*(14)
Score Mean ± SD 55.6 ± 10.6 55.9 ± 11.9 54.9 ± 9.9 46.8*# ± 12.1
Somatization Diagnosis (≥ 56) 58% (19) 74% (34) 52% (17) 30% (18)
Score Mean ± SD 55.4 ± 8.9 56.6 ± 11.4 55.9 ± 10.4 47.8*# ± 12.3
* Indicates significant difference with Group I (P = < 0.05)
# Indicates significant difference with Baseline values within the Group (P = < 0.001)
Table 5: Change in proportion of patients with employment status
Employment Status Group I Group II
Baseline At 12 months Baseline At 12 months
Employed 2 (6%) 2 (6%) 1 (2%) 16 (32%)*
Unemployed 2 (6%) 2 (6%) 8 (16%) 1 (2%)
Housewife 2 (6%) 2 (6%) 1 (2%) 1 (2%)
Disabled 26 (79%) 26 (79%) 38 (76%) 30 (60%)
Over 65 (yrs) 1 (3%) 1 (3%) 2 (4%) 2 (4%)
T o t a l 3 35 03 35 0
*Indicates significant difference (P < 0.01)BMC Anesthesiology 2005, 5:10 http://www.biomedcentral.com/1471-2253/5/10
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response to fluoroscopically-directed epidural steroid
injections and one-day percutaneous adhesiolysis.
Numerous studies have evaluated the effectiveness of spi-
nal endoscopic adhesiolysis [24-29,31]; however, these
studies utilized heterogenous inclusion criteria. Igarashi et
al [29] evaluated patients with degenerative lumbar spinal
stenosis. Manchikanti et al [26] evaluated only patients
with a history of previous surgical intervention. In
another study, Manchikanti et al [27] included patients
who had not previously undergone surgery (a total of
16%). Dashfield et al [31] included only non-surgical
patients. Geurts et al [24] reported results of spinal endo-
scopic adhesiolysis in 20 patients suffering with chronic
low back pain. They reported > 50% reduction in pain in
40% of the patients at 3 months, and 35% at 6, 9, and 12
months. Richardson et al [25] reported results in 38
patients, with 19 of those patients identified with failed
back surgery syndrome. They reported significant
improvement based on Visual Analogue Scale and func-
tional abilities. However, they have not reported data with
regards to the proportion of patients with sustained relief
at various time periods. Manchikanti et al [26,27] in two
different studies, reported 75% relief at 3 months, 40% at
6 months, and 22% at 12 months in post-lumbar
laminectomy patients; and, in a heterogenous group of
patients including both post laminectomy and non-surgi-
cal patients, 52% of the patients at 3 months, 21% of the
patients at 6 months, and 7% of the patients after 12
months. Igarashi et al [29] evaluated 58 patients with
degenerative lumbar spinal stenosis, dividing them into
two groups based on the presenting symptoms of either a
monosegmental group (n = 34) or a multisegmental
group (n = 24). They showed that relief of low back pain
was observed up to 12 months after epiduroscopy in both
groups, whereas relief of leg pain was evident up to 12
months after epiduroscopy in the monosegmental group,
and up to 3 months after epiduroscopy in the multiseg-
mental group. Dashfield et al [31] compared caudal epi-
dural steroid injections with targeted steroid placement
during spinal endoscopy for chronic sciatica in a prospec-
tive, randomized, double-blind trial. They randomized 60
patients with a 6-to 18-month history of sciatica to either
a targeted epidural local anesthetic and steroid placement
with a spinal endoscope, or caudal epidural local anes-
thetic and steroid placement. They defined sciatica as pain
in the distribution of lumbar nerve root, accompanied by
neurosensory and motor deficits, with or without back
pain. They excluded patients with history of previous spi-
nal surgery, coagulopathy, progressive motor neuron dis-
orders or peripheral vascular disease, and patients
receiving epidural corticosteroid injections within 3
months. No significant differences were found between
the groups for any of the measures at any time. However,
there were significant differences within both groups com-
pared with pre-treatment values. The results of the present
evaluation may not be compared to either the studies by
Igarashi et al [29] or by Dashfield et al [31].
Igarashi et al [29] evaluated patients only with spinal ste-
nosis. One-day percutaneous adhesiolysis also was shown
to be effective in refractory spinal stenosis [44]. However,
Igarashi et al [29] did not treat their patients with spinal
stenosis with percutaneous adhesiolysis, which is consid-
ered as a safer and more effective procedure. The study by
Dashfield et al [31] was performed in patients who were
not expected to have epidural fibrosis and who had not
been treated with either epidural steroid injections or with
1-day or 3-day percutaneous adhesiolysis. Consequently,
there was no significant difference noted between caudal
epidural steroid injections and targeted steroid placement
with spinal endoscopy. In clinical practice in the United
States, invasive intervention with spinal endoscopy as an
initial treatment is not widely accepted.
The most common and worrisome complications of spi-
nal endoscopy with adhesiolysis and injection of corticos-
teroids are related to dural puncture, spinal cord
compression, intravascular injection, vascular injury, cer-
ebral vascular or pulmonary embolus, infection, steroids,
instrumentation with endoscope, and administration of
high volumes of fluids potentially resulting in excessive
epidural hydrostatic pressures, resulting in blindness,
neurapraxia, numbness, intravascular injections, brain
damage, and death [23-30,45-58]. Even though no major
complications have been noted in this study, it is recom-
mended that all precautions be undertaken, along with
exhaustion of other modalities of treatments prior to
embarking on spinal endoscopic adhesiolysis considering
the safety and cost. The cost of the endoscope and the
procedure are higher than either caudal epidural steroid
injections or 1-day or 3-day percutaneous adhesiolysis
procedure. The safety and effectiveness of 1-day and 3-day
percutaneous adhesiolysis has been demonstrated
[21,22].
The present evaluation utilized early unblinding in some
patients, did not include a placebo group, and adapted a
randomization ratio of 2:3 instead of 1:1. Considering the
difficulties of recruiting patients to a double-blind trial,
the authors considered the best way to recruit patients and
give them a reasonable level of comfort was to offer addi-
tional treatment(s) if they failed the study, rather than
allowing them to suffer for a year. Based on this alloca-
tion, the authors managed to include an acceptable
number of patients. The control group for the study was
not a true placebo group since interventions of caudal epi-
dural steroid injections were used; nevertheless, the injec-
tions were ineffective in these patients. One of the
objectives of the study was to demonstrate whether epi-BMC Anesthesiology 2005, 5:10 http://www.biomedcentral.com/1471-2253/5/10
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dural steroid injections administered after adhesiolysis
are effective as opposed to traditional or fluoroscopically-
directed epidural steroid injections. In addition, this also
served to provide a level of comfort to patients enrolled in
the study since they knew they would receive some type of
active treatment rather than a placebo. The authors
believed that this type of randomization with a control
group receiving standard treatment to be more effective
and provide optimal results. A randomization process
with a 2:3 ratio was selected to convince patients to enroll
in the study, as they would have a higher chance of being
included in a treatment group rather than a control group.
The statistical validity was maintained throughout the
study and an intent-to-treat analysis was incorporated in
the study.
Trials of healthcare interventions are often described as
either explanatory or pragmatic [40,41]. Explanatory trials
generally measure efficacy – the benefit a treatment pro-
duces under ideal conditions. Consequently, explanatory
trials often use carefully-defined subjects in a well-con-
trolled research setting. By contrast, pragmatic trials, also
known as practical clinical trials, measure effectiveness –
benefit the treatment produces in routine clinical practice.
Tunis et al [40] commented on the prevalence and signif-
icance of gaps in knowledge about clinical effectiveness of
interventions and suboptimal evidence available to
answer the critical questions. Most systematic reviews per-
formed in interventional pain management include stud-
ies providing data not applicable to patients treated in
typical practice settings. Consequently, limited quantity
and quality of available scientific information impedes
the efforts of public and private health insurers in devel-
oping evidence-based coverage policies for many new and
existing technologies [59,60].
The substantial differences between explanatory and prag-
matic trials illustrate a paradigm shift to clinical practice.
Patient selection in an explanatory approach is based on
the principles of homogenous population, primarily aim-
ing to further scientific knowledge. However, in a prag-
matic or practical clinical trial, the design reflects
variations between patients that occur in real life clinical
settings, and aims to inform choices between treatments.
The authors consider this trial to be close to pragmatic or
practical rather than explanatory. Even with appropriate
randomization, the major focus of clinical research in the
modern era of medicine, multiple other sources of bias
may affect results. In this study, independent assessment
was utilized. However, without a placebo treatment, in
pragmatic approaches, the treatment response is the total
difference between two treatments, including both treat-
ment and associated placebo effects, as this will best
reflect the likely clinical response in practice [22,30,58,61-
65]. Practical clinical trials are expected to best address
questions about the risks, benefits, and cost of an inter-
vention as they would occur in routine clinical practice
[41]. Thus, the most distinctive features of practical clini-
cal trials are that they select patients from practices, either
simulating actual practices or actual clinical practices. In
addition, practical clinical trials often are designed to
compare viable alternative clinical strategies. This study
achieves both the distinctive features of practical clinical
trials by selecting the population from an actual clinical
practice and also by comparing viable alternative clinical
strategies.
This procedure may be considered as a replacement for
large bore catheter for percutaneous adhesiolysis, as we
have not derived any diagnostic information. However,
visualization of the scar tissue and freeing of the scar tis-
sue from the nerve root may provide some additional ben-
efit. The present day available catheters for percutaneous
adhesiolysis are smaller bore. Consequently, spinal
endoscopy with larger bore and improved flexibility
appears to have a role. Percutaneous adhesiolysis has
been shown to be an effective and safe procedure
[21,22,45,46]. However this study went beyond percuta-
neous adhesiolysis and selected the patients after insuffi-
cient response after 1-day percutaneous adhesiolysis.
The issue remains for the patients who have had success-
ful relief for 6 months or 12 months with regards to fur-
ther treatment when pain returns and functional status
deteriorates. Based on the present literature, with proper
indications and precautions, the procedure may be
repeated after approximately 6 months. In addition, the
authors believe that even if patients have not responded
previously to these procedures, if they have responded ini-
tially to spinal endoscopy, they may respond to 1-day or
3-day percutaneous adhesiolysis or even caudal epidural
steroid injections. However, published data is not availa-
ble at present to support this assumption and controlled
trials are recommended to evaluate this postulate. Addi-
tional effect from spinal endoscopic adhesiolysis may be
dependent on hydrostatic pressures created by the admin-
istration of sodium chloride solution which is not the case
with lesser volume percutaneous adhesiolysis. However,
percutaneous adhesiolysis also may be modified to
accommodate this feature.
Conclusion
This controlled trial demonstrates that spinal endoscopic
adhesiolysis reduces pain and improves functional and
psychological status without adverse effects up to 12
months.
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